“The White House is having ongoing conversations with the four major infant formula manufacturers — Reckitt, Abbott, Nestle/Gerber, and Perrigo — to work with them to identify transportation, logistical, and supplier hurdles to increasing production of formula at their US- and FDA-approved facilities, to expand the amount and speed of FDA-approved formula being shipped into the country, and ensure that formula is quickly moving to retailers from factories,” the White House official said.
There are also efforts to shore up the supply chain, with outreach to formula manufacturers’ suppliers.
“We are also contacting suppliers to infant formula manufacturers to inform them that their materials are critical for boosting U.S. infant formula production and they should prioritize their production and delivery,” the official noted.
During an appearance on CNN’s “New Day” on Monday, US Food and Drug Administration commissioner Dr. Robert Califf said the administration is “doing everything we can” to resolve the shortage.
Califf pointed to efforts to work with manufacturers to increase production, work on supply chain, work closely with Abbott to get its shuttered plant open as soon as possible. He suggested the FDA would make it possible for formula intended for other countries to become available in the US in a set of announcements expected “by the end of the day today.”
Pressed on how much of an impact that move will have, he said the situation more broadly will “gradually improve” over a “few weeks.” This Thursday, Califf testifies before the Agriculture Appropriations Subcommittee on the FDA’s 2023 budget request and oversight of infant formula.